Anti-Human CD337/NKp30 Monoclonal Antibody for IF/ICC, FC - O14931

Core Product Specifications and Parameters

Biological Background: Natural cytotoxicity triggering receptor 3 (CD337/NKp30) Function and Localization

• NKp30 (CD337) is a natural cytotoxicity triggering receptor (NCR3) that is selectively expressed on natural killer (NK) cells and weakly expressed in the spleen.
• It functions as an activating receptor at the cell membrane, triggering NK cell cytotoxicity upon binding to extracellular ligands such as BAG6 and NCR3LG1.
• NKp30 controls NK cell-mediated killing of tumor cells, playing a critical role in anti-tumor immunity.
• Engagement of NKp30 by BAG6 promotes myeloid dendritic cell (DC) maturation by inducing the release of TNFA and IFNG from NK cells and eliminating immature DCs.
• The protein is a transmembrane glycoprotein with an immunoglobulin domain, a signal peptide, and disulfide bonds; it undergoes alternative splicing.
• Subcellular localization is primarily the cell membrane.
• Tissue specificity: selectively expressed by all resting and activated NK cells and weakly expressed in spleen.

Experimental Guidance and Technical Tips

• The immunogen covers the extracellular region (amino acids 19–135) of human CD337/NKp30, suggesting suitability for detecting surface-expressed receptor in immunofluorescence and flow cytometry applications.
• As a rabbit monoclonal antibody, it may offer high specificity and lot-to-lot consistency; consider including appropriate isotype controls in experiments.
• For intracellular flow cytometry (FC intra), optimization of fixation and permeabilization conditions is recommended to preserve epitope accessibility.
• Cross-reactivity is stated for human; validate in relevant human samples or cell lines known to express NKp30, such as primary NK cells.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers and research laboratories with streamlined access to high-quality IVD raw materials, including validated antibody pairs, optimized monoclonal/polyclonal antibodies, and bulk ancillary reagents. For studies involving natural killer cell biology or immuno-oncology targets, we offer a reliable supply of antibodies against receptors like NKp30, along with rare-target sourcing support. Our integrated approach helps bridge the gap from concept to clinical development, ensuring robust material access for every research stage.